Literature DB >> 22002422

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

Heiko Braak1, Dietmar R Thal, Estifanos Ghebremedhin, Kelly Del Tredici.   

Abstract

Two thousand three hundred and thirty two nonselected brains from 1- to 100-year-old individuals were examined using immunocytochemistry (AT8) and Gallyas silver staining for abnormal tau; immunocytochemistry (4G8) and Campbell-Switzer staining were used for the detection ofβ-amyloid. A total of 342 cases was negative in the Gallyas stain but when restaged for AT8 only 10 were immunonegative. Fifty-eight cases had subcortical tau predominantly in the locus coeruleus, but there was no abnormal cortical tau (subcortical Stages a-c). Cortical involvement (abnormal tau in neurites) was identified first in the transentorhinal region (Stage 1a, 38 cases). Transentorhinal pyramidal cells displayed pretangle material (Stage 1b, 236 cases). Pretangles gradually became argyrophilic neurofibrillary tangles (NFTs) that progressed in parallel with NFT Stages I to VI. Pretangles restricted to subcortical sites were seen chiefly at younger ages. Of the total cases, 1,031 (44.2%) had β-amyloid plaques. The first plaques occurred in the neocortex after the onset of tauopathy in the brainstem. Plaques generally developed in the 40s in 4% of all cases, culminating in their tenth decade (75%). β-amyloid plaques and NFTs were significantly correlated (p < 0.0001). These data suggest that tauopathy associated with sporadic Alzheimer disease may begin earlier than previously thought and possibly in the lower brainstem rather than in the transentorhinal region.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002422     DOI: 10.1097/NEN.0b013e318232a379

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  647 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

2.  A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting.

Authors:  Andrea Vergallo; Cecilia Carlesi; Cristina Pagni; Filippo Sean Giorgi; Filippo Baldacci; Lucia Petrozzi; Roberto Ceravolo; Gloria Tognoni; Gabriele Siciliano; Ubaldo Bonuccelli
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

3.  On the origin of tau seeding activity in Alzheimer's disease.

Authors:  Helmut Heinsen; Lea T Grinberg
Journal:  Acta Neuropathol       Date:  2018-07-23       Impact factor: 17.088

4.  Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study.

Authors:  Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

5.  Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.

Authors:  Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen
Journal:  Biol Psychiatry       Date:  2020-01-07       Impact factor: 13.382

6.  Functional connectivity and graph theory in preclinical Alzheimer's disease.

Authors:  Matthew R Brier; Jewell B Thomas; Anne M Fagan; Jason Hassenstab; David M Holtzman; Tammie L Benzinger; John C Morris; Beau M Ances
Journal:  Neurobiol Aging       Date:  2013-10-18       Impact factor: 4.673

7.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

8.  Genetic risk for Alzheimer's disease and functional brain connectivity in children and adolescents.

Authors:  Luiza Kvitko Axelrud; João Ricardo Sato; Marcos Leite Santoro; Fernanda Talarico; Daniel Samuel Pine; Luis Augusto Rohde; Andre Zugman; Edson Amaro Junior; Rodrigo Affonseca Bressan; Rodrigo Grassi-Oliveira; Pedro Mario Pan; Maurício Scopel Hoffmann; Andre Rafael Simioni; Salvador Martin Guinjoan; Hakon Hakonarson; Elisa Brietzke; Ary Gadelha; Renata Pellegrino da Silva; Marcelo Queiroz Hoexter; Euripedes Constantino Miguel; Sintia Iole Belangero; Giovanni Abrahão Salum
Journal:  Neurobiol Aging       Date:  2019-07-06       Impact factor: 4.673

9.  Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults.

Authors:  Niklas Mattsson; Philip Insel; Rachel Nosheny; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Duygu Tosun; Michael Weiner
Journal:  Neurobiol Aging       Date:  2013-10-01       Impact factor: 4.673

Review 10.  Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Authors:  Thomas Arendt; Jens Stieler; Max Holzer
Journal:  J Neural Transm (Vienna)       Date:  2014-12-06       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.